Femasys (FEMY) Competitors $1.17 +0.01 (+0.86%) Closing price 05/1/2025 03:50 PM EasternExtended Trading$1.17 0.00 (0.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock FEMY vs. LUCD, OBIO, AVR, INFU, KRMD, SKIN, MGRM, ICAD, NSPR, and MBOTShould you be buying Femasys stock or one of its competitors? The main competitors of Femasys include Lucid Diagnostics (LUCD), Orchestra BioMed (OBIO), Anteris Technologies Global (AVR), InfuSystem (INFU), KORU Medical Systems (KRMD), Beauty Health (SKIN), Monogram Orthopaedics (MGRM), iCAD (ICAD), InspireMD (NSPR), and Microbot Medical (MBOT). These companies are all part of the "medical equipment" industry. Femasys vs. Lucid Diagnostics Orchestra BioMed Anteris Technologies Global InfuSystem KORU Medical Systems Beauty Health Monogram Orthopaedics iCAD InspireMD Microbot Medical Femasys (NASDAQ:FEMY) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, community ranking, institutional ownership, earnings, profitability and risk. Does the media prefer FEMY or LUCD? In the previous week, Lucid Diagnostics had 1 more articles in the media than Femasys. MarketBeat recorded 3 mentions for Lucid Diagnostics and 2 mentions for Femasys. Femasys' average media sentiment score of 1.43 beat Lucid Diagnostics' score of 0.46 indicating that Femasys is being referred to more favorably in the media. Company Overall Sentiment Femasys Positive Lucid Diagnostics Neutral Does the MarketBeat Community believe in FEMY or LUCD? Lucid Diagnostics received 4 more outperform votes than Femasys when rated by MarketBeat users. However, 75.00% of users gave Femasys an outperform vote while only 68.97% of users gave Lucid Diagnostics an outperform vote. CompanyUnderperformOutperformFemasysOutperform Votes3675.00% Underperform Votes1225.00% Lucid DiagnosticsOutperform Votes4068.97% Underperform Votes1831.03% Is FEMY or LUCD more profitable? Lucid Diagnostics has a net margin of -1,069.87% compared to Femasys' net margin of -1,435.77%. Lucid Diagnostics' return on equity of 0.00% beat Femasys' return on equity.Company Net Margins Return on Equity Return on Assets Femasys-1,435.77% -141.49% -82.30% Lucid Diagnostics -1,069.87%N/A -123.54% Do institutionals & insiders believe in FEMY or LUCD? 65.3% of Femasys shares are held by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are held by institutional investors. 12.3% of Femasys shares are held by insiders. Comparatively, 8.8% of Lucid Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has preferable earnings and valuation, FEMY or LUCD? Femasys has higher earnings, but lower revenue than Lucid Diagnostics. Femasys is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFemasys$1.63M19.50-$14.25M-$0.85-1.38Lucid Diagnostics$4.35M31.28-$52.67M-$1.08-1.19 Which has more volatility and risk, FEMY or LUCD? Femasys has a beta of -2.55, meaning that its share price is 355% less volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Do analysts prefer FEMY or LUCD? Femasys presently has a consensus price target of $11.50, indicating a potential upside of 882.91%. Lucid Diagnostics has a consensus price target of $3.50, indicating a potential upside of 171.32%. Given Femasys' higher probable upside, equities research analysts clearly believe Femasys is more favorable than Lucid Diagnostics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Femasys 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Lucid Diagnostics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 SummaryLucid Diagnostics beats Femasys on 12 of the 19 factors compared between the two stocks. Get Femasys News Delivered to You Automatically Sign up to receive the latest news and ratings for FEMY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FEMY vs. The Competition Export to ExcelMetricFemasysSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.77M$4.33B$5.53B$7.93BDividend YieldN/A39.93%5.11%4.22%P/E Ratio-1.4430.0322.5918.54Price / Sales19.5055.31401.35103.29Price / CashN/A51.0838.1834.62Price / Book1.386.056.774.25Net Income-$14.25M$68.71M$3.22B$248.18M7 Day Performance-4.88%-0.24%1.39%1.03%1 Month Performance-9.30%-2.90%2.78%2.70%1 Year Performance-5.26%21.00%15.85%4.05% Femasys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FEMYFemasys3.4109 of 5 stars$1.17+0.9%$11.50+882.9%-10.0%$31.77M$1.63M-1.4430Upcoming EarningsShort Interest ↓Positive NewsLUCDLucid Diagnostics2.4507 of 5 stars$1.20-0.8%$3.50+191.7%+46.8%$108.91M$4.35M-1.0570Positive NewsOBIOOrchestra BioMed2.7761 of 5 stars$2.84-0.4%$15.00+428.2%-37.5%$108.81M$2.64M-1.764Gap UpAVRAnteris Technologies GlobalN/A$3.14+9.0%$16.50+425.5%N/A$103.57M$2.71M0.00138News CoveragePositive NewsINFUInfuSystem1.4965 of 5 stars$4.91flat$13.00+164.8%N/A$103.19M$134.86M81.85410News CoveragePositive NewsKRMDKORU Medical Systems3.2459 of 5 stars$2.24-1.3%$4.70+109.8%+22.2%$102.94M$33.65M-8.9680Upcoming EarningsNews CoverageSKINBeauty Health1.9973 of 5 stars$0.82-2.9%$2.50+204.4%-67.5%$102.86M$334.29M-1.961,030Upcoming EarningsMGRMMonogram Orthopaedics2.4493 of 5 stars$2.65-1.9%$5.40+103.8%+47.7%$93.52M$364,999.00-5.6428Gap UpICADiCAD0.5742 of 5 stars$3.03-5.9%N/A+139.2%$82.92M$19.61M-23.31140High Trading VolumeNSPRInspireMD2.3203 of 5 stars$2.60+0.4%$4.75+82.7%+32.7%$79.65M$7.01M-3.4750MBOTMicrobot Medical1.8276 of 5 stars$2.23-10.4%$9.00+303.6%+152.1%$77.48MN/A-2.7920Positive News Related Companies and Tools Related Companies Lucid Diagnostics Alternatives Orchestra BioMed Alternatives Anteris Technologies Global Alternatives InfuSystem Alternatives KORU Medical Systems Alternatives Beauty Health Alternatives Monogram Orthopaedics Alternatives iCAD Alternatives InspireMD Alternatives Microbot Medical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FEMY) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Femasys Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Femasys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
